Suppr超能文献

经导管主动脉瓣植入术前和术后的利尿剂治疗:一项丹麦全国性研究。

Diuretic treatment before and after transcatheter aortic valve implantation: A Danish nationwide study.

机构信息

Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Department of Cardiology, Herlev-Gentofte University Hospital, Hellerup, Denmark.

出版信息

PLoS One. 2023 Mar 16;18(3):e0282636. doi: 10.1371/journal.pone.0282636. eCollection 2023.

Abstract

OBJECTIVES

We examined loop diuretic treatment before and 1-year after transcatheter aortic valve implantation (TAVI), as a proxy for changes in symptom severity and secondly assessed how changes in loop diuretics related to mortality risk.

BACKGROUND

Randomized clinical trials suggest that approximately one third of patients undergoing TAVI do not achieve symptom relief, but "all-comer" data are lacking.

METHODS

Using Danish nationwide registries, we identified all citizens, who underwent TAVI from 2008 to 2019 and were alive at 1-year post-discharge. Loop diuretic treatment pre-TAVI and at 1-year post-TAVI were assessed and grouped as receiving 1) no-loop diuretics; 2) low: 1-40 mg of furosemide (or equivalent bumetanide) daily; 3) intermediate: 41-120 mg of furosemide daily; or 4) high: >120 mg furosemide daily.

RESULTS

Among the 4431 patients undergoing TAVI, 2173 (49%) patients were not treated with loop diuretics at the time of TAVI, 918 (21%) had low-loop diuretics, 881 (20%) had intermediate-loop diuretics, and 459 (10%) had high-loop diuretics. At 1-year post-TAVI, 893 (20%) patients had increased, 1010 (23%) had reduced, and 2528 (57%) had unchanged loop diuretic treatment. The cumulative 5-year risk of death in patients surviving one year, was 61% (95% CI: 56.4% to 65.3%) in patients with increased and 47% (95% CI: 44.9% to 49.9%) in patients with reduced/unchanged loop diuretic treatment, respectively. In multivariable Cox proportional hazard analysis, increased loop diuretic treatment was associated with a higher risk of death compared with reduced/unchanged loop diuretic treatment (Hazard ratio: 1.4; 95% CI: 1.22 to 1.52).

CONCLUSIONS

Among patients undergoing TAVI, surviving one year, one fifth of patients had increased loop diuretic treatment, and a little over one fifth had reduced loop diuretic treatment 1-year post-procedure. In patients with increased diuretic treatment, the risk of death was higher compared to those with reduced/unchanged loop diuretic treatment.

摘要

目的

我们研究了经导管主动脉瓣植入术(TAVI)前后的袢利尿剂治疗情况,以此作为症状严重程度变化的替代指标,其次评估袢利尿剂的变化与死亡风险的关系。

背景

随机临床试验表明,大约三分之一接受 TAVI 的患者没有缓解症状,但缺乏“所有患者”的数据。

方法

利用丹麦全国性登记处,我们确定了所有在 2008 年至 2019 年期间接受 TAVI 治疗且在出院后 1 年内存活的公民。评估了 TAVI 前和 TAVI 后 1 年的袢利尿剂治疗情况,并将其分为以下 4 组:1)未使用袢利尿剂;2)低剂量:每天 1-40mg 呋塞米(或等效布美他尼);3)中剂量:每天 41-120mg 呋塞米;或 4)高剂量:每天>120mg 呋塞米。

结果

在接受 TAVI 的 4431 名患者中,2173 名(49%)患者在 TAVI 时未接受袢利尿剂治疗,918 名(21%)患者接受低剂量袢利尿剂治疗,881 名(20%)患者接受中剂量袢利尿剂治疗,459 名(10%)患者接受高剂量袢利尿剂治疗。TAVI 后 1 年,893 名(20%)患者增加了袢利尿剂治疗,1010 名(23%)患者减少了袢利尿剂治疗,2528 名(57%)患者未改变袢利尿剂治疗。在存活 1 年的患者中,5 年内死亡的累积风险分别为:增加袢利尿剂治疗组为 61%(95%CI:56.4%至 65.3%),减少/未改变袢利尿剂治疗组为 47%(95%CI:44.9%至 49.9%)。多变量 Cox 比例风险分析显示,与减少/未改变袢利尿剂治疗相比,增加袢利尿剂治疗与死亡风险增加相关(风险比:1.4;95%CI:1.22 至 1.52)。

结论

在接受 TAVI 治疗且存活 1 年的患者中,五分之一的患者增加了袢利尿剂治疗,超过五分之一的患者在术后 1 年减少了袢利尿剂治疗。与减少/未改变的袢利尿剂治疗相比,增加利尿剂治疗的患者死亡风险更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b71c/10019742/1e3884df9869/pone.0282636.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验